loading
前日終値:
$1.58
開ける:
$1.57
24時間の取引高:
43,578
Relative Volume:
0.12
時価総額:
$160.08M
収益:
-
当期純損益:
$-13.73M
株価収益率:
-11.96
EPS:
-0.13
ネットキャッシュフロー:
$-3.92M
1週間 パフォーマンス:
-1.58%
1か月 パフォーマンス:
+14.34%
6か月 パフォーマンス:
+123.36%
1年 パフォーマンス:
+75.59%
1日の値動き範囲:
Value
$1.55
$1.61
1週間の範囲:
Value
$1.5299
$1.81
52週間の値動き範囲:
Value
$0.6295
$1.91

Tiziana Life Sciences Ltd Stock (TLSA) Company Profile

Name
名前
Tiziana Life Sciences Ltd
Name
セクター
Healthcare (1174)
Name
電話
-
Name
住所
-
Name
職員
9
Name
Twitter
@tizianals
Name
次回の収益日
2024-05-27
Name
最新のSEC提出書
Name
TLSA's Discussions on Twitter

TLSA を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
TLSA
Tiziana Life Sciences Ltd
1.55 160.08M 0 -13.73M -3.92M -0.13
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
453.71 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
541.42 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
319.34 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
561.96 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
240.76 28.51B 3.81B -644.79M -669.77M -6.24

Tiziana Life Sciences Ltd Stock (TLSA) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2020-12-22 開始されました B. Riley Securities Buy
2018-12-17 開始されました Laidlaw Buy

Tiziana Life Sciences Ltd (TLSA) 最新ニュース

pulisher
Jun 16, 2025

Tiziana Life Sciences Ltd (TLSA) Stock: A Year of Stock Market Ups and Downs - investchronicle.com

Jun 16, 2025
pulisher
Jun 16, 2025

Promising Penny Stocks To Consider In June 2025 - simplywall.st

Jun 16, 2025
pulisher
Jun 13, 2025

Tiziana: Scope Of Foralumab Goes Beyond That Of Multiple Sclerosis Targeting (NASDAQ:TLSA) - Seeking Alpha

Jun 13, 2025
pulisher
Jun 13, 2025

Tiziana Life Sciences Adds Fifth Site for Phase 2 Foralumab Trial in Multiple Sclerosis - MarketScreener

Jun 13, 2025
pulisher
Jun 13, 2025

Small cap wrap: Tiziana Life Sciences, Challenger Energy, Arrow Exploration... - Proactive financial news

Jun 13, 2025
pulisher
Jun 13, 2025

Tiziana expands Phase 2 MS trial to fifth site, commences patient dosing - Proactive financial news

Jun 13, 2025
pulisher
Jun 13, 2025

Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center - The Manila Times

Jun 13, 2025
pulisher
Jun 13, 2025

Breakthrough Multiple Sclerosis Treatment Enters Next Phase as Weill Cornell Joins Major Clinical Trial - Stock Titan

Jun 13, 2025
pulisher
Jun 13, 2025

Market movers: RH, Tiziana, Archer Aviation... - Proactive Investors

Jun 13, 2025
pulisher
Jun 13, 2025

Shares of Tiziana Life Sciences (TLSA) Climb on CEO's Upcoming P - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Tiziana shares rise on presentation date for foralumab data - Seeking Alpha

Jun 13, 2025
pulisher
Jun 13, 2025

Tiziana CEO to present clinical advances of intranasal foralumab at BIO 2025 - Proactive financial news

Jun 13, 2025
pulisher
Jun 13, 2025

Tiziana Life Sciences to Present at the Bio International Convention - The Manila Times

Jun 13, 2025
pulisher
Jun 13, 2025

Revolutionary Intranasal Treatment for MS and Alzheimer's: Tiziana CEO Reveals Latest Clinical Findings at BIO 2025 - Stock Titan

Jun 13, 2025
pulisher
May 27, 2025

Tiziana Life Sciences Ltd (TLSA) Stock: A Comprehensive 52-Week Review - investchronicle.com

May 27, 2025
pulisher
May 27, 2025

Tiziana Life Sciences (NASDAQ:TLSA) Stock Price Up 15.3% – Still a Buy? - Defense World

May 27, 2025
pulisher
May 23, 2025

TLSA Advances Alzheimer's Treatment with Innovative Nasal Spray - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease - marketscreener.com

May 23, 2025
pulisher
May 23, 2025

Tiziana Life Sciences Announces Interview Highlighting Intranasa - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease | TLSA Stock News - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Tiziana Life Sciences Announces Breakthrough Advancement in Moderate Alzheimer’s Treatment with Intranasal Foralumab - Nasdaq

May 23, 2025
pulisher
May 23, 2025

Breakthrough: First Alzheimer's Patient Shows Improvement with Revolutionary Nasal Antibody Treatment - Stock Titan

May 23, 2025
pulisher
May 16, 2025

Journal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer's Disease - BioSpace

May 16, 2025
pulisher
May 16, 2025

Small cap wrap: Lancaster Resources, Cerro de Pasco, Tiziana Life Sciences, Nano One Materials... - Proactive financial news

May 16, 2025
pulisher
May 15, 2025

Tiziana reports reduction in microglial activation in Alzheimer’s case treated with nasal foralumab - Proactive financial news

May 15, 2025
pulisher
May 15, 2025

TLSA: Tiziana Life Sciences Study Shows Promise for Alzheimer's Treatment | TLSA Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Journal of Clinical Nuclear Medicine Publishes Results of Tiziana's Nasal Foralumab in Study Treating Moderate Alzheimer's Disease - The Manila Times

May 15, 2025
pulisher
May 15, 2025

Journal Of Clinical Nuclear Medicine Publishes Results Of Tiziana’S Nasal Foralumab In Study Treating Moderate Alzheimer's Disease - MENAFN.com

May 15, 2025
pulisher
May 15, 2025

Journal of Clinical Nuclear Medicine Publishes Results of - GlobeNewswire

May 15, 2025
pulisher
May 15, 2025

Revolutionary Nasal Treatment Reduces Brain Inflammation in Moderate Alzheimer's Patient, Harvard Study Shows - Stock Titan

May 15, 2025
pulisher
May 12, 2025

Tiziana Life Sciences chairman increases stake to over 37% - Proactive financial news

May 12, 2025
pulisher
May 12, 2025

Executive Chairman Increases Stake in Tiziana Life Sciences (TLS - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Tiziana Life Sciences Announces Purchase of Shares by Chairman - The Manila Times

May 12, 2025
pulisher
May 10, 2025

Tiziana reports promising Alzheimer’s treatment results By Investing.com - Investing.com Nigeria

May 10, 2025
pulisher
May 10, 2025

Tiziana reports promising Alzheimer’s treatment results - Investing.com

May 10, 2025
pulisher
May 09, 2025

Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab - BioSpace

May 09, 2025
pulisher
May 09, 2025

Tiziana Reports PET data sees reduced neuroinflammation in patient treated with Intranasal Therapy - Proactive Investors

May 09, 2025
pulisher
May 09, 2025

Market movers: Lyft, US Gold, Tiziana Life Sciences... - Proactive Investors

May 09, 2025
pulisher
May 09, 2025

Tiziana Life Sciences reports reduced brain inflammation in Alzheimer’s patient treated with nasal foralumab - Proactive Investors

May 09, 2025
pulisher
May 09, 2025

TLSA: Tiziana Life Sciences Reports Positive PET Scan Results in Alzheimer's Treatment | TLSA Stock News - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Tiziana stock gains on data for Alzheimer's drug (TLSA:NASDAQ) - Seeking Alpha

May 09, 2025
pulisher
May 09, 2025

Tiziana Life Sciences Announces Significant Reduction In Microglia Activation In PET Scan Of Moderate Alzheimer's Patient Treated With Intranasal Foralumab - MENAFN.com

May 09, 2025
pulisher
May 09, 2025

Tiziana Life Sciences Announces Significant Reduction in - GlobeNewswire

May 09, 2025
pulisher
May 08, 2025

Tiziana Life Sciences’ intranasal MS candidate shows promise in open-label study - PMLiVE

May 08, 2025
pulisher
May 06, 2025

Small cap wrap: Tiziana Life Sciences, Millennial Potash, Century LIthium... - Proactive financial news

May 06, 2025
pulisher
May 06, 2025

Tiziana shares surge 21% on promising multiple sclerosis data - Proactive financial news

May 06, 2025
pulisher
May 06, 2025

Tiziana rises on positive results in multiple sclerosis treatment study - Seeking Alpha

May 06, 2025
pulisher
May 06, 2025

Tiziana reports encouraging results for nasal MS drug in early study - Proactive Investors

May 06, 2025
pulisher
May 06, 2025

TLSA's Nasal Foralumab Shows Promise in MS Treatment Study | TLS - GuruFocus

May 06, 2025
pulisher
May 06, 2025

TLSA's Nasal Foralumab Shows Promise in MS Treatment Study | TLSA Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Clinical Trial Success: Revolutionary Nasal Spray Halts Multiple Sclerosis Progression in Landmark Study - Stock Titan

May 06, 2025

Tiziana Life Sciences Ltd (TLSA) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$20.77
price up icon 0.56%
$36.22
price up icon 0.51%
$20.72
price down icon 2.68%
$98.67
price down icon 2.04%
$107.07
price up icon 0.55%
biotechnology ONC
$241.09
price up icon 0.19%
大文字化:     |  ボリューム (24 時間):